Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Daiichi Sankyo
Accenture
Healthtrust
Deloitte
Baxter
McKesson
Moodys
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,774,122

« Back to Dashboard

Summary for Patent: 6,774,122
Title: Formulation
Abstract:The invention relates to a novel sustained release pharmaceutical formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-t riene-3,17.beta.-diol, more particularly to a formulation adapted for administration by injection containing the compound 7.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-t riene-3,17.beta.-diol in solution in a ricinoleate vehicle which additionally comprises at least one alcohol and a non-aqueous ester solvent which is miscible in the ricinoleate vehicle.
Inventor(s): Evans; John R (Macclesfield, GB), Grundy; Rosalind U (Macclesfield, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/756,291
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,774,122
Patent Claims: 1. A method of treating a hormonal dependent benign or malignant disease of the breast or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle, whereby a therapeutically significant blood plasma fulvestrant concentration of at least 2.5 ngml.sup.-1 is attained for at least 2 weeks after injection.

2. The method as claimed in claim 1 wherein the benign or malignant disease is breast cancer.

3. The method as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for at least 4 weeks after injection.

4. The method as claimed in claim 1 wherein the blood plasma fulvestrant concentration is attained for 2 to 5 weeks after injection.

5. A method of treating a hormonal dependent benign or malignant disease of the brass or reproductive tract by administration to a human in need of such treatment an intra-muscular injection of a pharmaceutical formulation comprising fulvestrant, a mixture of 10% weight of ethanol per volume of formulation, 10% weight of benzyl alcohol per volume of formulation and 15% weight of benzyl benzoate per volume of formulation and a sufficient amount of a castor oil vehicle whereby the formulation comprises at least 45 mgml of fulvestrant.

6. The method as claimed in claim 1 or 5 wherein the total volume of the formulation administered to said human is 6 ml or less, and the concentration of fulvestrant in said formulation is at least 45 mgm.sup.-1.

7. The method as claimed in claim 1 or 5 wherein the total volume of the formulation administered to said human is 6 ml or less, and the total amount of fulvestrant in said volume of formulation is 250 mg or more.

8. The method as claimed in claim 7 wherein the total volume of formulation is from 5 to 5.25 ml, and the total amount of fulvestrant in said volume of formulation is 250 mg.

9. The method as claimed in claim 5 wherein the benign or malignant disease is breast cancer.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Argus Health
McKesson
Julphar
Fuji
Colorcon
UBS
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.